TaiwanJ Pharmaceuticals Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include live… Read more
TaiwanJ Pharmaceuticals Co., Ltd. (6549) - Total Assets
Latest total assets as of June 2025: NT$88.15 Million TWD
Based on the latest financial reports, TaiwanJ Pharmaceuticals Co., Ltd. (6549) holds total assets worth NT$88.15 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TaiwanJ Pharmaceuticals Co., Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how TaiwanJ Pharmaceuticals Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TaiwanJ Pharmaceuticals Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
TaiwanJ Pharmaceuticals Co., Ltd.'s total assets of NT$88.15 Million consist of 92.5% current assets and 7.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 47.3% |
| Accounts Receivable | NT$97.00K | 0.1% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how TaiwanJ Pharmaceuticals Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TaiwanJ Pharmaceuticals Co., Ltd.'s current assets represent 92.5% of total assets in 2024, an increase from 7.6% in 2019.
- Cash Position: Cash and equivalents constituted 47.3% of total assets in 2024, up from 36.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 47.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
TaiwanJ Pharmaceuticals Co., Ltd. Competitors by Total Assets
Key competitors of TaiwanJ Pharmaceuticals Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TaiwanJ Pharmaceuticals Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TaiwanJ Pharmaceuticals Co., Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TaiwanJ Pharmaceuticals Co., Ltd. is currently not profitable relative to its asset base.
TaiwanJ Pharmaceuticals Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.85 | 10.95 | 7.87 |
| Quick Ratio | 18.85 | 10.95 | 7.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$74.83 Million | NT$ 48.98 Million | NT$ 49.02 Million |
TaiwanJ Pharmaceuticals Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between TaiwanJ Pharmaceuticals Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.30 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 37.0% |
| Total Assets | NT$100.77 Million |
| Market Capitalization | $16.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values TaiwanJ Pharmaceuticals Co., Ltd.'s assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: TaiwanJ Pharmaceuticals Co., Ltd.'s assets grew by 37.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TaiwanJ Pharmaceuticals Co., Ltd. (2019–2024)
The table below shows the annual total assets of TaiwanJ Pharmaceuticals Co., Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$100.77 Million | +36.99% |
| 2023-12-31 | NT$73.56 Million | -7.81% |
| 2022-12-31 | NT$79.79 Million | -53.16% |
| 2021-12-31 | NT$170.33 Million | -7.02% |
| 2020-12-31 | NT$183.20 Million | +14.59% |
| 2019-12-31 | NT$159.87 Million | -- |